Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 497 (7448), 211-6

Hypothalamic Programming of Systemic Ageing Involving IKK-β, NF-κB and GnRH

Affiliations

Hypothalamic Programming of Systemic Ageing Involving IKK-β, NF-κB and GnRH

Guo Zhang et al. Nature.

Abstract

Ageing is a result of gradual and overall functional deteriorations across the body; however, it is unknown whether an individual tissue primarily works to mediate the ageing progress and control lifespan. Here we show that the hypothalamus is important for the development of whole-body ageing in mice, and that the underlying basis involves hypothalamic immunity mediated by IκB kinase-β (IKK-β), nuclear factor κB (NF-κB) and related microglia-neuron immune crosstalk. Several interventional models were developed showing that ageing retardation and lifespan extension are achieved in mice by preventing ageing-related hypothalamic or brain IKK-β and NF-κB activation. Mechanistic studies further revealed that IKK-β and NF-κB inhibit gonadotropin-releasing hormone (GnRH) to mediate ageing-related hypothalamic GnRH decline, and GnRH treatment amends ageing-impaired neurogenesis and decelerates ageing. In conclusion, the hypothalamus has a programmatic role in ageing development via immune-neuroendocrine integration, and immune inhibition or GnRH restoration in the hypothalamus/brain represent two potential strategies for optimizing lifespan and combating ageing-related health problems.

Figures

Figure 1
Figure 1. Aging-dependent hypothalamic NF-κB activation
57BL/6 mice (chow-fed males) were analyzed at young (3–4 months) age (Y), middle-old (11–13 months) age (M), and old (22–24 months) age (O). a&b. Hypothalami were analyzed via Western blots. b: Intensity of p-RelA normalized by RelA (au: arbitrary unit). c&d. Mice received MBH injections of lentiviral GFP controlled by NF-κB response element (NF-κB/RE), and following ~3-week recovery, brain sections were made to reveal GFP and NeuN stainining. DAPI staining shows entire cell populations. Bar = 25 µm. d: Percentages of cells co-expressing GFP and NeuN (GFP+NeuN+) among NeuN-expressing cells (NeuN+) in the MBH. **P < 0.01, ***P < 0.001; n = 6 (b) and 3 (d) per group. Error bars reflect mean ± SEM.
Figure 2
Figure 2. Aging manipulations by hypothalamic IKKβ/NF-κB
MBH-IKKβ, MBH-IκBα and MBH-Con mice were generated using ~18-month-old C57BL/6 mice (chow-fed males). a. Dual synapsin (Syn) promoter-directed lentiviral vectors. b. Lifespan of these mice (n = 23 – 31 mice per group). c&d. Mice at ~6 months post gene delivery were assessed for cognition via T-maze (c) and muscle endurance (d). e–h: Mice were scarified at 8~10 months post gene delivery for measuring muscle (quadriceps) fiber size (e), dermal thickness (f), bone mass (g), and tail tendon breaking time (h). *P < 0.05, **P < 0.01; MBH-Con: n = 23 (b), 9 (c), 6 (d), 3 (e&f), 4 (g), and 7 (h); MBH-IKKβ: n = 24 (b), 10 (c), 6 (d), 3 (e&f), 4 (g), and 5 (h); MBH-IκBα: n = 31 (b), 12 (c), 7 (d), 3 (e&f), 6 (g), and 8 (h). Error bars reflect mean ± SEM.
Figure 3
Figure 3. Role of hypothalamic microglia in aging
a–c Brain sections of young (Y), middle-old (M) and old (O) C57BL/6 mice were analyzed for hypothalamic microglia. a: Representative images of immunostaining. Bar = 25 µm. b&c: Numbers of cells expressing Iba-1 (Iba-1+) (b) or TNF-α (TNF-α+) (c) in the arcuate nucleus. d. Middle-old IKKβlox/lox mice received bilateral MBH injections of lentiviral CD11b promoter-driven Cre (CD11b) vs. control (Con). At 1 month vs. 8 months post injection, brain sections were made for Iba-1 and TNF-α staining (images in suppl. Fig. 4c). Mice generated at a young age provided normal references. Data show numbers of cells immunoreactive for Iba-1, TNF-α or both in the arcuate nucleus. e–i. Mice described in Fig. 3e were generated at a middle-old age and assessed at old ages for cognition (e–g), muscle endurance (h), and tail tendon breaking time (i). MWM data included time in target vs. a representative off-target (Off-T) quadrant in probe trials. *P < 0.05, **P < 0.01, ***P < 0.001; n = 4 (b&c) and 3 (d) per group; Con: n = 6 (e–g, i) and 9 (h); CD11b: n = 5 (e–g) and 6 (h&i). Error bars reflect mean ± SEM.
Figure 4
Figure 4. Genetic longevity by brain-specific IKKβ knockout
N/IKKβlox/lox mice (N/IKKβl/l) and littermate WT in males were maintained on a chow since weaning. a&b. Young (3 months) vs. old age (18–20 months) mice were tested for cognition (a) and muscle endurance (b). MWM data included time in target northwest (NW) vs. off-target northeast (NE), southwest (SW) and southeast (SE) quadrants in probe trials. c–h. Young (3–4 months) vs. old (20–24 months) mice were scarified for assessing muscle (quadriceps) fiber size (c), dermal thickness (d–f), bone mass (g), and tail tendon breaking time (h). i. Lifespan follow-up (n = 20 in WT and n = 25 in N/IKKβl/l). *P < 0.05, **P < 0.01; young WT: n = 10 (b), 3 (c&e), 5 (f), 6 (g) and 8 (h); young N/IKKβl/l: n = 14 (b), 3 (c,e,f), 6 (g) and 8 (h); old WT: n = 10 (a), 7 (b), 3 (c&e), 5 (f&g), and 6 (h); old N/IKKβl/l n = 10 (a), 7 (b), 3 (c,e,f), and 6 (g&h). Error bars reflect mean ± SEM.
Figure 5
Figure 5. Inhibition of GnRH by IKKβ/NF-κB
a–c Hypothalamic GnRH mRNA of indicated mice. d–g. GT1–7 cells were transfected with CAIKKβ, RelA or DNIκBα vs. control (Con) plasmid (d,e,g), co-transfected with GnRH-promoter luciferase plasmid (e&f), or together with RelA shRNA (sh-RelA) vs. control shRNA (sh-Con) plasmid (f), and were measure for GnRH release (d), GnRH promoter (e&f), and c-Fos, c-Jun, PKCα and PKCδ mRNA levels (g). h. GnRH promoter activities were measured for GT1–7 cells transfected with GnRH-promoter luciferase plasmid, co-transfected with c-Jun or c-Fos plasmid vs. control plasmid (Con), or treated with TPA vs. vehicle (Veh). i. GnRH promoter activities were measured for GT1–7 cells transfected with GnRH-promoter luciferase plasmid, co-transfected with CAIKKβ vs. control (Con) plasmid, and with c-Fos/c-Jun shRNA plasmids (sh-c-Fos/sh-c-Jun) vs. scramble shRNA control (sh-Con). j. Summarized schematic model. *P < 0.05, **P < 0.01, ***P < 0.001; n = 12 (a&e) and 3 (f–i) per group, and n = 6 (b), 8 (c) and 4 (d) in Con, n = 8 (b) and 6 (d) in IKKβ, and n = 8 (c) and 6 (d) in IκBα. Error bars reflect mean ± SEM.
Figure 6
Figure 6. Central and systemic actions of GnRH in counteracting aging
a–d C57BL/6 mice at an old age were subjected to neurogenesis (a&b) and survival (c&d) assays, as detailed in methods. a: BrdU staining of MBH and dentate gyrus (DG) in neurogenesis assay. Bar = 50 µm. b&c: BrdU-labeled cells (BrdU+) in the MBH (b) and DG (c) in neurogenesis assay. d&e: Survival of BrdU-labeled (BrdU+) cells in the MBH (d) and DG (e) in survival assay. f–i. MBH-IKKβ and MBH-Con mice at an old age were daily injected subcutaneously with GnRH vs. vehicle for 5 weeks, and analyzed for muscle endurance (f), skeletal muscle fibers(g), skin (h), and cognition (i) (see suppl. Fig. 10 for additional data). *P < 0.05, **P < 0.01, ***P < 0.001; n = 4 (b–e), 7 (f), and 3 (g&h) per group, and n = 12 (Con, Veh), 7 (Con, GnRH), 7 (IKKβ, Veh), and 8 (IKKβ, GnRH) (i). Error bars reflect mean ± SEM.

Comment in

Similar articles

See all similar articles

Cited by 239 PubMed Central articles

See all "Cited by" articles

References

Reference List

    1. Miller RA. Genes against aging. J. Gerontol. A Biol. Sci. Med. Sci. 2012;67:495–502. - PMC - PubMed
    1. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004;430:631–639. - PMC - PubMed
    1. Masoro EJ. Overview of caloric restriction and ageing. Mech. Ageing Dev. 2005;126:913–922. - PubMed
    1. Finch CE. Neurons, glia, and plasticity in normal brain aging. Adv. Gerontol. 2002;10:35–39. - PubMed
    1. Zitnik G, Martin GM. Age-related decline in neurogenesis: old cells or old environment? J. Neurosci. Res. 2002;70:258–263. - PubMed

Supplementary Reference List

    1. Meng Q, Cai D. Defective hypothalamic autophagy directs the central pathogenesis of obesity via the IkappaB kinase beta (IKKbeta)/NF-kappaB pathway. J. Biol. Chem. 2011;286:32324–32332. - PMC - PubMed
    1. Banks WA, et al. Effects of a growth hormone-releasing hormone antagonist on telomerase activity, oxidative stress, longevity, and aging in mice. Proc. Natl. Acad. Sci. U. S. A. 2010;107:22272–22277. - PMC - PubMed
    1. Tillerson JL, Miller GW. Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of parkinsonism. J. Neurosci. Methods. 2003;123:189–200. - PubMed
    1. Mueller JM, Pahl HL. Assaying NF-kappa B and AP-1 DNA-binding and transcriptional activity. Methods Mol. Biol. 2000;99:205–216. - PubMed
    1. Flurkey K, Papaconstantinou J, Miller RA, Harrison DE. Lifespan extension and delayed immune and collagen aging in mutant mice with defects in growth hormone production. Proc. Natl. Acad. Sci. U. S. A. 2001;98:6736–6741. - PMC - PubMed

Publication types

MeSH terms

Feedback